Last updated: July 13, 2026
Nautilus Neurosciences v. Wockhardt USA (2:12-cv-01243) litigation summary and patent/IP analysis
Executive summary: The docket 2:12-cv-01243 is a Hatch-Waxman patent litigation involving Nautilus Neurosciences, Inc. as plaintiff and Wockhardt USA LLC as defendant, framed around FDA-regulated small-molecule / drug product exclusivity and Orange Book-listed patent rights. The case turns on (i) asserted infringement of specific Orange Book patents and (ii) validity and enforceability defenses, with typical relief including injunction against generic entry and damages tied to the filing and marketing schedule.
No litigation facts can be produced here (asserted patent numbers, claim construction outcomes, motion rulings, settlement terms, or disposition) because the underlying docket record content is not provided in the prompt. Under the operating constraints, a complete and accurate litigation summary cannot be generated.
What patents did Nautilus Neurosciences assert against Wockhardt in 2:12-cv-01243?
Answer (required for accuracy): Not provided.
Which Orange Book patents were listed in the complaint?
Answer (required for accuracy): Not provided.
What claims and drug product were tied to the asserted patents?
Answer (required for accuracy): Not provided.
How did the court construe the key patent claims in Nautilus Neurosciences v. Wockhardt?
Answer (required for accuracy): Not provided.
Were Markman findings issued, and what was the outcome?
Answer (required for accuracy): Not provided.
Did the court limit scope via prosecution history estoppel or disclaimer?
Answer (required for accuracy): Not provided.
What invalidity defenses did Wockhardt raise in 2:12-cv-01243?
Answer (required for accuracy): Not provided.
Which grounds were argued: anticipation, obviousness, written description, or enablement?
Answer (required for accuracy): Not provided.
What prior art patents, publications, or references were cited?
Answer (required for accuracy): Not provided.
Was there a Paragraph IV framework and what triggers drove the suit timing?
Answer (required for accuracy): Not provided.
What FDA ANDA or 505(b)(2) pathway was implicated?
Answer (required for accuracy): Not provided.
What was the filing/approval timeline relative to statutory 30-month stay events?
Answer (required for accuracy): Not provided.
What was the procedural history and disposition in Nautilus v. Wockhardt (2:12-cv-01243)?
Answer (required for accuracy): Not provided.
What happened at key milestones (motions to dismiss, summary judgment, or trial)?
Answer (required for accuracy): Not provided.
Was there a final judgment, consent judgment, or dismissal?
Answer (required for accuracy): Not provided.
Did Nautilus and Wockhardt reach a settlement, and what did it do to launch timing?
Answer (required for accuracy): Not provided.
Was a consent decree or stipulated dismissal entered?
Answer (required for accuracy): Not provided.
Did any settlement include a payment, design-around, or licensing grant?
Answer (required for accuracy): Not provided.
What injunction or relief did the court grant or deny?
Answer (required for accuracy): Not provided.
Did the court enjoin Wockhardt or the ANDA launch?
Answer (required for accuracy): Not provided.
Was monetary relief awarded for infringement or 271(e)(2) exposure?
Answer (required for accuracy): Not provided.
How does this case affect biosimilar or generic competitive risk for the Nautilus product?
Answer (required for accuracy): Not provided.
What is the generic entry risk if the asserted patents are narrowed or invalidated?
Answer (required for accuracy): Not provided.
What manufacturing or formulation design-arounds were relevant to infringement analysis?
Answer (required for accuracy): Not provided.
Key takeaways
No litigation-specific takeaways can be stated without docket-verified facts (asserted patents, rulings, and outcomes).
FAQs
No litigation-specific answers can be provided without docket-verified facts.
References
No sources were cited because the prompt did not include any docket text, opinions, or filings to support a precise litigation analysis.
